Cargando…
P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430639/ http://dx.doi.org/10.1097/01.HS9.0000847620.60858.05 |
| _version_ | 1784779826617384960 |
|---|---|
| author | McMillan, A. Haioun, C. Sancho, J.-M. Viardot, A. Rodriguez Izquierdo, A. Donato Martin, E. M. García-Sancho, A. M. Sandoval-Sus, J. Tilly, H. Vandenberghe, E. Hirata, J. Choudhry, P. Chang, Y. M. Musick, L. Matasar, M. |
| author_facet | McMillan, A. Haioun, C. Sancho, J.-M. Viardot, A. Rodriguez Izquierdo, A. Donato Martin, E. M. García-Sancho, A. M. Sandoval-Sus, J. Tilly, H. Vandenberghe, E. Hirata, J. Choudhry, P. Chang, Y. M. Musick, L. Matasar, M. |
| author_sort | McMillan, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430639 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94306392022-08-31 P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA McMillan, A. Haioun, C. Sancho, J.-M. Viardot, A. Rodriguez Izquierdo, A. Donato Martin, E. M. García-Sancho, A. M. Sandoval-Sus, J. Tilly, H. Vandenberghe, E. Hirata, J. Choudhry, P. Chang, Y. M. Musick, L. Matasar, M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430639/ http://dx.doi.org/10.1097/01.HS9.0000847620.60858.05 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters McMillan, A. Haioun, C. Sancho, J.-M. Viardot, A. Rodriguez Izquierdo, A. Donato Martin, E. M. García-Sancho, A. M. Sandoval-Sus, J. Tilly, H. Vandenberghe, E. Hirata, J. Choudhry, P. Chang, Y. M. Musick, L. Matasar, M. P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title | P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_full | P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_fullStr | P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_full_unstemmed | P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_short | P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_sort | p1189: initial safety run-in results of the phase iii polargo trial: polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory diffuse large b-cell lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430639/ http://dx.doi.org/10.1097/01.HS9.0000847620.60858.05 |
| work_keys_str_mv | AT mcmillana p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT haiounc p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sanchojm p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT viardota p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT rodriguezizquierdoa p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT donatomartinem p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT garciasanchoam p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sandovalsusj p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT tillyh p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT vandenberghee p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT hirataj p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT choudhryp p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT changym p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT musickl p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT matasarm p1189initialsafetyruninresultsofthephaseiiipolargotrialpolatuzumabvedotinplusrituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma |